Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets

Junhu Tai, Munsoo Han, Taehoon Kim

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)


Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.

Original languageEnglish
Article number5523
JournalInternational journal of molecular sciences
Issue number10
Publication statusPublished - 2022 May 1

Bibliographical note

Funding Information:
Funding: This research was supported by the Basic Science Research Program, National Research Foundation of Korea, funded by the Ministry of Science and Technology and the Ministry of Science, ICT & Future Planning (2017R1A2B2003575, NRF-2020R1A2C1006398), the Ministry of Science and ICT (2020R1C1C1012288), Korea, under the ICT Creative Consilience program (IITP-2022-2020-0-01819) supervised by the Institute for Information & Communications Technology Planning & Evaluation (IITP), the Korea Health Technology R&D Project (HI17C0387), Korea Health Industry Development Institute (KHIDI), and the Ministry of Health and Welfare.

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.


  • biologics
  • chronic rhinosinusitis
  • immunity
  • monoclonal antibody
  • therapeutic strategy

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets'. Together they form a unique fingerprint.

Cite this